explore -WSS

explore

author：entertainment 2025-09-29 16:33:10 - browse：34

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Listen: Biogen's potential pivot, & Illumina's next chapter

WSS

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Mega Millions pot grows to $1.25 billion after no winner

How to fix cancer clinical trials' diversity problem

Adults seen as increasingly susceptible to measles

Trump indictment: Who are the 'co

Micronoma's microbiome cancer diagnostic approach under fire

leisure time

explore

Wikipedia

Hollywood unions extend contract negotiations for actors

Medicaid rebukes states for mistakenly disenrolling children

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Amazon expands telehealth clinic nationwide

Guidelines to prevent youth baseball injuries need more muscle

EQRx, failed developer of low

Psychedelics group wrestles with new pharma identity

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Anesthesiologist group: stop taking Ozempic before surgery

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

focus

Amazon expands telehealth clinic nationwide

A rare thyroid diagnosis led to unexpected, all

Wildfire pollution widens asthma inequities on Long Island

Adults seen as increasingly susceptible to measles

House transparency, PBM reform bill gains bipartisan support

'Make People Better': The CRISPR babies story you probably don't know

knowledge

hotspot

focus

knowledge